What are the top 3 biotech stocks with the highest short-term upside potential?

The deep research logic is organized as follows: 

Okay, let's tackle this question about the top 3 biotech stocks with the highest short-term upside potential. First, I need to check the references provided to see what data is available. The user is asking for short-term upside, so I should look for recent news, financial results, and any catalysts that could drive stock prices up quickly.

Looking at the references, there are several mentions of biotech companies. Let's start with the queries. Reference 1 and 2 are queries about biotech stocks with specific moving average and volume criteria, but both returned 0 results. That's a bit of a dead end. Reference 8 is another query about the top 3 biotech stocks with the highest short-term upside potential, but it also has 0 results. Hmm, that's not helpful.

Next, let's check the articles. Reference 9 talks about IO Biotech's Cylembio missing its primary endpoint but showing promise in specific subgroups. The analyst maintained a Buy rating with a $14 price target. That's a positive sign, especially if the stock is undervalued. The current price isn't provided, but the price target suggests upside potential.

Reference 12 mentions Qihan Biotech getting FDA clearance for an IND for a CAR-T therapy. That's a significant regulatory milestone, which can be a catalyst for stock movement. The company is focusing on autoimmune diseases, which have high unmet needs, so this could attract investor interest.

Reference 19 is a query result showing 5 biotech stocks with accelerating moving averages and volume increases. The top 5 include CASI Pharmaceuticals, Prelude, PMV Pharmaceuticals, PDS Biotechnology, and Karyopharm. These might be candidates, but the user is asking for the top 3. However, the data in Reference 19 is from 2025-08-20, which matches the current time, so it's relevant. The stocks listed have high volume growth and positive price changes, indicating potential short-term momentum.

Reference 16 discusses 4 biotech stocks poised for resurgence,